To the Editor: The recent editorial on community-acquired pneumonia (CAP) stated that “even in an era in which penicillin resistance appears to be increasing among some Streptococcus pneumoniae isolates, there have been no documented failures of high-dose penicillin in treating pneumococcal pneumonia or bacteraemia”.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- Lakeside Medical Practice, Warilla, NSW.
Correspondence: patbradley@optusnet.com.au
- 1. Charles PGP, Johnson PDR, Grayson ML. Conundrums in community-acquired pneumonia [editorial]. Med J Aust 2006; 185: 131-132. <MJA full text>
- 2. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia. Chest 2003; 123: 1503-1511.
- 3. Waterer GW. Optimal antibiotic treatment in severe pneumococcal pneumonia — time for real answers. Eur J Clin Microbiol Infect Dis 2005; 24: 691-692.
- 4. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837-1842.
Online responses are no longer available. Please refer to our instructions for authors page for more information.